Carlos García Porrúa

Dr. Carlos García Porrúa

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Carlos García PorrúaCarlos García Porrúa
Carlos García Porrúa
EHElena Heras-Recuero
Elena Heras-Recuero
TBTeresa Blázquez-Sánchez
Teresa Blázquez-Sánchez
ATArantxa Torres-Rosello
Arantxa Torres-Rosello
Santos CastañedaSantos Castañeda
Santos Castañeda
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Background/Objectives: Polymyalgia Rheumatica (PMR) is an inflammatory condition that primarily affects individuals aged 50 and older, especially in Western countries. Although glucocorticoids are the cornerstone of PMR treatment, these drugs are associated with side effects, making it advisable to use them for the shortest duration possible. However, tapering or discontinuation of glucocorticoids often leads to disease relapses. In this review, we focus on the traditional management of PMR, as well as the potential for therapies that may reduce glucocorticoid use. Special attention is given to the efficacy of biologic agents in PMR management. Methods: A literature review, primarily based on articles published in PubMed, was conducted. In addition to discussing various glucocorticoids and conventional disease-modifying drugs used for the management of isolated PMR, this review specifically focused on the information reported regarding new therapies, with particular emphasis on biologic agents. Results: Prednisone or prednisolone at a dose ranging between 12.5 and 25 mg/day is the agreed-upon treatment for PMR. Due to the side effects associated with prolonged glucocorticoid use and the high frequency of relapses when glucocorticoids are tapered, glucocorticoid-sparing agents have emerged as tools in the management of PMR. Methotrexate has traditionally been the conventional disease-modifying antirheumatic drug (DMARD) unanimously recommended for use in PMR. Other conventional DMARDs, such as leflunomide, have shown promising results but require further study. The use of biologic agents has marked a significant step forward in the management of PMR. While anti-TNF agents failed to provide beneficial effects in isolated PMR, anti-IL-6 receptor agents, such as tocilizumab and sarilumab, have demonstrated efficacy in reducing relapse frequency, lowering the cumulative glucocorticoid burden, and achieving long-term remission of the disease. Other biologic agents, many of which have been used in giant cell arteritis, as well as Janus kinase (JAK) inhibitors, are currently under investigation. Conclusions: Glucocorticoids are the primary treatment for isolated PMR but are associated with comorbidities, especially in patients with pre-existing conditions or frequent relapses. Glucocorticoid-sparing agents, such as methotrexate and biologics, in particular tocilizumab and sarilumab, offer alternatives, improving symptoms and reducing glucocorticoid use. While biologic agents reduce long-term side effects and help achieve disease remission, their use must consider potential side effects and higher costs compared to traditional therapies.


1 January 2019 in Reumatología Clínica
Verified
Journal Article
Closed access
NRNoelia Alvarez Rivas
Noelia Alvarez Rivas
TRTomas R. Vazquez Rodriguez
Tomas R. Vazquez Rodriguez
JFJose A. Miranda Filloy
Jose A. Miranda Filloy
Carlos García PorrúaCarlos García Porrúa
Carlos García Porrúa
AFAmalia Sanchez-Andrade Fernández
Amalia Sanchez-Andrade Fernández

1 March 2021 in Reumatología Clínica
Verified
Journal Article
Closed access
Carlos García PorrúaCarlos García Porrúa
Carlos García Porrúa
FPFrancisco José Maceiras Pan
Francisco José Maceiras Pan
JMJosé Antonio Mosquera Martínez
José Antonio Mosquera Martínez
LCLoreto Carmona
Loreto Carmona
BRBlanca Correa Rey
Blanca Correa Rey
JTJosé Antonio Pinto Tasende
José Antonio Pinto Tasende

20 December 2018 in Medicina Clinica
Verified
Journal Article
Closed access
NANoelia Alvarez-Rivas
Noelia Alvarez-Rivas
TVTomás R. Vazquez-Rodriguez
Tomás R. Vazquez-Rodriguez
Carlos García PorrúaCarlos García Porrúa
Carlos García Porrúa

26 October 2023 in Reumatología Clínica (English Edition)
Verified
Journal Article
Closed access
CUCarlota Iñiguez Ubiaga
Carlota Iñiguez Ubiaga
Carlos García PorrúaCarlos García Porrúa
Carlos García Porrúa
JTJosé Antonio Pinto Tasende
José Antonio Pinto Tasende
LULorena Paula Iñiguez Ubiaga
Lorena Paula Iñiguez Ubiaga
AFAmalia Sánchez-Andrade Fernandez
Amalia Sánchez-Andrade Fernandez